Identify response rates of vestibular schwannomas in NF2-related Schwanomatosis to treatment with losartan alone or combined with other treatments.
✦ The floor
Discussion
Signed responses from readers of the wire.
Evidence is too preliminary (small single-institution case series, no control group) to justify adding losartan to NF2-SWN management outside of a research protocol; no actionable practice change at this time.
Repurposing an inexpensive, widely available antihypertensive as a potential medical therapy for NF2-SWN vestibular schwannomas could open a low-cost treatment avenue for a condition with very limited systemic options.
- 01Single-institution case series in Otology & Neurotology examining losartan for NF2-SWN vestibular schwannomas.
- 02Losartan was evaluated alone and in combination with other therapies.
- 03NF2-SWN is a rare genetic disorder causing multiple nerve-sheath tumors, including bilateral vestibular schwannomas.
- 04Case series design limits causal conclusions; no randomisation or matched controls were used.
- 05Findings are hypothesis-generating and support design of prospective controlled trials.
Losartan, alone or in combination with other therapies, produces measurable responses in vestibular schwannomas in NF2-SWN patients.
studypartially supported- PMID
- 42826387
- DOI
- 10.1097/MAO.0000000000005087.
- Journal
- Otology & Neurotology
- Publication type
- case_series
- Evidence level
- 4
- Population
- Patients with NF2-related schwannomatosis (NF2-SWN) harbouring vestibular schwannomas at a single institution
- Intervention
- Losartan (alone or in combination with other therapies)
Primary outcomes
Tumor response rate of vestibular schwannomas to losartan